Experimental drug aims to help control weight in 44-Week trial

NCT ID NCT06703021

Summary

This study is testing whether a new medication called aleniglipron (GSBR-1290) can help people with obesity or overweight manage their weight when combined with diet and exercise. Researchers will compare the drug to a placebo in 82 participants over 44 weeks to see if it's safe and effective. The study focuses on adults who have a body mass index (BMI) of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • ACCESS II Research Site

    Glendale, California, 91206, United States

  • ACCESS II Research Site

    Montclair, California, 91763, United States

  • ACCESS II Research Site

    Valparaiso, Indiana, 46383, United States

  • ACCESS II Research Site

    West Des Moines, Iowa, 50265, United States

  • ACCESS II Research Site

    Medford, Oregon, 97504, United States

  • ACCESS II Research Site

    East Greenwich, Rhode Island, 02818, United States

  • ACCESS II Research Site

    North Charleston, South Carolina, 29405, United States

  • ACCESS II Research Site

    Dallas, Texas, 75042, United States

  • ACCESS II Research Site

    San Antonio, Texas, 78240, United States

  • ACCESS II Research Site

    West Jordan, Utah, 84088, United States

Conditions

Explore the condition pages connected to this study.